[Federal Register Volume 86, Number 124 (Thursday, July 1, 2021)]
[Notices]
[Pages 35100-35101]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14129]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: David Yang at 240-695-6406 or 
[email protected]. Licensing information may be obtained by 
communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin

    Description of Technology: Atopic dermatitis (AD) is a common, 
recurrent, chronic inflammatory skin disease that is a cause of 
considerable economic and social burden. It is one of the most 
prevalent skin disorders, affecting ~25% of children in developed and 
developing countries and is expected to continue to escalate. This 
increased rate of incidence has changed the focus of research on AD 
toward epidemiology, prevention, and treatment.

[[Page 35101]]

    Scientists at NIAID have developed novel topical formulations that 
promote the growth of health-associated strains of commensal bacteria 
and inhibit disease-associated bacteria, thereby enhancing skin health.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Over-the-counter formulations--this invention could be readily 
incorporated into popular body lotions or other skincare products to 
make ``enhanced''/``microbiome-friendly'' versions that promote the 
growth of health associated bacterial

    Competitive Advantages:

 Benign safety profile with multiple mechanisms of action
 Proven enhancement of beneficial microbiota
 Can be readily incorporated into existing products

    Development Stage:

 Pre-clinical

    Inventors: Carlos Castillo and Ian Myles, MD, MPH, both of NIAID.
    Publications: Castillo, Carlos, et al. ``Assessing the effects of 
common topical exposures on skin bacteria associated with atopic 
dermatitis'', Skin Health and Disease, 2021.05.07.
    Intellectual Property: HHS Reference No. E-100-2021-0; US 
provisional application No. 63/175,368 filed on April 15, 2021.
    Licensing Contact: To license this technology, please contact David 
Yang at 240-695-6406 or [email protected] and reference E-100-2021-0.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact David Yang at 240-695-6406 or 
[email protected].

    Dated: June 24, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-14129 Filed 6-30-21; 8:45 am]
BILLING CODE 4140-01-P